Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
A small molecule cocktail eyedrop for endogenous RPE regeneration in an AMD model
Author Affiliations & Notes
  • Rana Muhammad Shoaib
    Surgery (Ophthalmology), Children's Hospital Los Angeles, Los Angeles, California, United States
    Ophthalmology, University of Southern California Keck School of Medicine, Los Angeles, California, United States
  • Aregnazan Sandrosyan
    Surgery (Ophthalmology), Children's Hospital Los Angeles, Los Angeles, California, United States
    Ophthalmology, University of Southern California Keck School of Medicine, Los Angeles, California, United States
  • Biraj Mahato
    Surgery (Ophthalmology), Children's Hospital Los Angeles, Los Angeles, California, United States
    Ophthalmology, University of Southern California Keck School of Medicine, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Rana Muhammad Shoaib None; Aregnazan Sandrosyan None; Biraj Mahato None
  • Footnotes
    Support  Knights Templar Eye Foundation, Glaucoma Research Foundation, Children's Hospital Los Angeles Start up
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6084. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rana Muhammad Shoaib, Aregnazan Sandrosyan, Biraj Mahato; A small molecule cocktail eyedrop for endogenous RPE regeneration in an AMD model. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6084.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age-related macular degeneration (AMD) leads to blindness in millions of individuals globally, primarily due to the degeneration and demise of the retinal pigment epithelium (RPE). At present, there are no effective treatments available to regenerate lost RPEs as a result of AMD. Pluripotent stem cells emerged as an attractive method to replace lost RPEs and restore vision in these patients. However, these methods are cumbersome, time consuming and outcome with variable quality of RPEs making it challenging for clinical applications. Developing therapies that specifically target the stimulation of endogenous RPE regeneration offers a compelling approach to treat AMD and other RPE degenerative diseases. In this study, we present a straightforward chemical-based approach to stimulate RPE regeneration from Muller cells both in vitro and in vivo.

Methods : A combination of a six-chemical cocktail plus two factors was administered as eye drops in both normal and sodium iodate-injured mice, allowing observation of subsequent responses in Muller cells, including proliferation, migration, and differentiation using immunofluorescence. To track cell lineages, an AAV2-GLAST-GFP reporter and GLAST-CreERT;Ai9 mice were employed following the administration of the eye drops. In addition, human primary Muller cells were subjected to the chemical cocktail for in vitro reprogramming and were analyzed using immunofluorescence, alongside a Lenti-BEST1-GFP promoter reporter.

Results : We observed chemical cocktail eyedrop application can effectively regenerate RPEs from Müller cells, both uninjured and sodium iodate injured retina. These RPEs displayed a cobblestone-like morphology, express bestrophin1 (BEST1) and were highly pigmented, indicating their resemblance to bonafide RPEs. Moreover, the same chemical cocktail was able to reprogram human primary Muller cells into hexagonal, pigmented, and RPE65+ and BEST1-GFP+ RPE cells. Lineage tracing experiments utilizing AAV2 GLAST-GFP and GLAST-CRE-Tdtomato mice provided confirmation of the Müller cell origin of the newly generated RPEs

Conclusions : We successfully developed an endogenous RPE regeneration protocol from Müller cells using a chemical cocktail both in vivo and in vitro.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×